KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short term Debt (2016 - 2025)

Historic Short term Debt for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $630.9 million.

  • Ionis Pharmaceuticals' Short term Debt rose 131882.97% to $630.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $630.9 million, marking a year-over-year increase of 131882.97%. This contributed to the annual value of $44.3 million for FY2023, which is N/A changed from last year.
  • Ionis Pharmaceuticals' Short term Debt amounted to $630.9 million in Q3 2025, which was up 131882.97% from $630.1 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Short term Debt's 5-year high stood at $630.9 million during Q3 2025, with a 5-year trough of $3.5 million in Q4 2021.
  • In the last 5 years, Ionis Pharmaceuticals' Short term Debt had a median value of $44.4 million in 2024 and averaged $126.3 million.
  • Examining YoY changes over the last 5 years, Ionis Pharmaceuticals' Short term Debt showed a top increase of 138954.22% in 2021 and a maximum decrease of 9885.82% in 2021.
  • Over the past 5 years, Ionis Pharmaceuticals' Short term Debt (Quarter) stood at $3.5 million in 2021, then surged by 40.95% to $5.0 million in 2022, then skyrocketed by 791.99% to $44.3 million in 2023, then rose by 0.3% to $44.5 million in 2024, then surged by 1318.83% to $630.9 million in 2025.
  • Its last three reported values are $630.9 million in Q3 2025, $630.1 million for Q2 2025, and $44.5 million during Q3 2024.